Carcinoma, Small Cell

• 

  Subject Areas on Research

  • A cost analysis of hematopoietic colony-stimulating factors. 
  • A genetically defined disease model reveals that urothelial cells can initiate divergent bladder cancer phenotypes. 
  • A multi-center phase II study of weekly topotecan as second-line therapy for small cell lung cancer. 
  • A phase I study of dose-dense topotecan given upfront to standard therapy in patients with small cell lung cancer. 
  • A phase I/II trial of etoposide and cisplatin in extensive small cell lung cancer: a cancer and leukemia group B study. 
  • A phase II study evaluating the efficacy of carboplatin, etoposide, and paclitaxel with granulocyte colony-stimulating factor in patients with stage IIIB and IV non-small cell lung cancer and extensive small cell lung cancer. 
  • A phase II study of paclitaxel and granulocyte colony-stimulating factor in previously untreated patients with extensive-stage small cell lung cancer: a study of the North Central Cancer Treatment Group. 
  • A phase II study of recombinant interferon-gamma following combination chemotherapy for patients with extensive small cell lung cancer. CALGB. 
  • A phase III trial evaluating the combination of cisplatin, etoposide, and radiation therapy with or without tamoxifen in patients with limited-stage small cell lung cancer: Cancer and Leukemia Group B Study (9235). 
  • A promoter polymorphism (-77T>C) of DNA repair gene XRCC1 is associated with risk of lung cancer in relation to tobacco smoking. 
  • A prospective comparison of fiberoptic transbronchial needle aspiration and bronchial biopsy for bronchoscopically visible lung carcinoma. 
  • A randomized trial to compare intravenous and oral etoposide in combination with cisplatin for the treatment of small cell lung cancer. 
  • A unique tripartite collision tumor of the esophagus: A case report. 
  • Abrogation of the RB-p16 tumor suppressor pathway in human lung cancer. 
  • Alternative Splicing Provides a Novel Molecular Mechanism for Prostatic Small-cell Neuroendocrine Carcinoma. 
  • An unusual cause of late pain and effusion after total knee arthroplasty: pulmonary hypertrophic osteoarthropathy. A case report. 
  • Anticancer antibodies for lung cancer. 
  • Antitumor activity of a monoclonal antibody directed against gastrin-releasing peptide in patients with small cell lung cancer. 
  • Autocrine growth factors and neuroendocrine markers in the development of small-cell lung cancer. 
  • BW2258U89: a GRP receptor antagonist which inhibits small cell lung cancer growth. 
  • Bilateral vocal cord paresis as a presenting sign of paraneoplastic syndrome: case report. 
  • Biology of small cell lung cancer. 
  • Biphenotypic sarcoma with characteristics of both a Ewing sarcoma and a desmoplastic small round cell tumor. 
  • CD10/neutral endopeptidase 24.11 hydrolyzes bombesin-like peptides and regulates the growth of small cell carcinomas of the lung. 
  • CD44 expression is a feature of prostatic small cell carcinoma and distinguishes it from its mimickers. 
  • Calcitonin elevation in small cell lung cancer without ectopic production. 
  • Characterization of delta opioid receptors in lung cancer using a novel nonpeptidic ligand. 
  • Cisplatin plus etoposide consolidation following cyclophosphamide, doxorubicin, and vincristine in limited small-cell lung cancer. 
  • Cisplatin, irinotecan, and bevacizumab for untreated extensive-stage small-cell lung cancer: CALGB 30306, a phase II study. 
  • Clinical practice. Lung cancer screening. 
  • Clonality of combined tumors. 
  • Co-amplification of a novel cyclophilin-like gene (PPIE) with L-myc in small cell lung cancer cell lines. 
  • Combination chemotherapy with or without thoracic radiotherapy in limited-stage small-cell lung cancer: a randomized trial of the Southeastern Cancer Study Group. 
  • Comparison of whole-body FDG-PET to bone scan for detection of bone metastases in patients with a new diagnosis of lung cancer. 
  • Comprehensive serial molecular profiling of an "N of 1" exceptional non-responder with metastatic prostate cancer progressing to small cell carcinoma on treatment. 
  • Continuous somatosensory evoked potential monitoring during brain tumor resection. Report of four cases and review of the literature. 
  • Controlled aspiration of subretinal fluid in the diagnosis of carcinoma metastatic to the choroid. 
  • Correlation between erythrocyte CR1 reduction and other blood proteinase markers in patients with malignant and inflammatory disorders. 
  • Correlation of expression of bombesin-like peptides and receptors with growth inhibition by an anti-bombesin antibody in small-cell lung cancer cell lines. 
  • Cyclocreatine in cancer chemotherapy. 
  • Cytomorphology of primary small-cell (Merkel-cell) carcinoma of the skin in fine needle aspirates. 
  • DEK expression in Merkel cell carcinoma and small cell carcinoma. 
  • Desmoplastic small round cell tumor masquerading as advanced ovarian cancer. 
  • Desmoplastic small round cell tumor: using FISH as an ancillary technique to support cytologic diagnosis in an unusual case. 
  • Differential inactivation of CDKN2 and Rb protein in non-small-cell and small-cell lung cancer cell lines. 
  • Down-regulation of ADRB2 expression is associated with small cell neuroendocrine prostate cancer and adverse clinical outcomes in castration-resistant prostate cancer. 
  • ERG-TMPRSS2 rearrangement is shared by concurrent prostatic adenocarcinoma and prostatic small cell carcinoma and absent in small cell carcinoma of the urinary bladder: evidence supporting monoclonal origin. 
  • Eaton-Lambert syndrome: a clinical and electrophysiological study of a patient treated with 4-aminopyridine. 
  • Electron microscopy in selection of patients with small cell carcinoma of the lung for medical versus surgical therapy. 
  • Eosinophilic intracytoplasmic globules in pulmonary adenocarcinomas: a histochemical, immunohistochemical, and ultrastructural study of six cases. 
  • Etoposide (VP-16) and cytosine arabinoside in the treatment of relapsed small-cell lung cancer. 
  • Etoposide, ifosfamide and cisplatin (VIP) plus concurrent radiation therapy for previously untreated limited small cell lung cancer (SCLC): a Hoosier Oncology Group (HOG) phase II study. 
  • F-18-FDG-PET/CT imaging of small cell carcinoma of the colon. 
  • FDG-PET imaging in patients with paraneoplastic syndromes and suspected small cell lung cancer. 
  • FHIT and FRA3B 3p14.2 allele loss are common in lung cancer and preneoplastic bronchial lesions and are associated with cancer-related FHIT cDNA splicing aberrations. 
  • FOXA2 is a sensitive and specific marker for small cell neuroendocrine carcinoma of the prostate. 
  • Foreign accent syndrome as a heralding manifestation of transformation to small cell neuroendocrine prostate cancer. 
  • Frequent TMPRSS2-ERG rearrangement in prostatic small cell carcinoma detected by fluorescence in situ hybridization: the superiority of fluorescence in situ hybridization over ERG immunohistochemistry. 
  • G-CSF as prophylaxis of febrile neutropenia in SCLC. 
  • Gastrin-releasing peptide gene expression in small cell and large cell undifferentiated lung carcinomas. 
  • Genetic analysis of second primary lung cancers in patients surviving small cell lung cancer. 
  • Germline and somatic SMARCA4 mutations characterize small cell carcinoma of the ovary, hypercalcemic type. 
  • Glioblastoma multiforme with small cell neuronal-like component: association with human neurotropic JC virus. 
  • Imaging bronchogenic carcinoma. 
  • Imaging lung cancer. 
  • Immunotoxin Therapy for Lung Cancer. 
  • Impact of extent of surgery on survival in patients with small nonfunctional pancreatic neuroendocrine tumors in the United States. 
  • In vitro determination of thymidine-3H labeling index in human solid tumors. 
  • Increased androgen receptor gene copy number is associated with TMPRSS2-ERG rearrangement in prostatic small cell carcinoma. 
  • Inhibition of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway but not the MEK/ERK pathway attenuates laminin-mediated small cell lung cancer cellular survival and resistance to imatinib mesylate or chemotherapy. 
  • Intercellular junctions and tumor behavior in lung cancer. 
  • Intercellular junctions and tumor stage in small cell carcinoma of the lung. 
  • Interleukin-2 activity in patients with extensive small-cell lung cancer: a phase II trial of Cancer and Leukemia Group B. 
  • Lambert-Eaton myasthenic syndrome (LEMS). Clinical and electrodiagnostic features and response to therapy in 59 patients. 
  • Lambert-Eaton myasthenic syndrome: electrodiagnostic findings and response to treatment. 
  • Lambert-Eaton myasthenic syndrome: the lack of short-term in vitro effects of serum factors on neuromuscular transmission. 
  • Limited-stage small-cell lung cancer (stages I-III): observations from the National Cancer Data Base. 
  • Lithium carbonate in patients with small cell lung cancer receiving combination chemotherapy. 
  • Lung cancer heterogeneity: a blinded and randomized study of 100 consecutive cases. 
  • Lung cancer in Florida. Risks associated with residence in the central Florida phosphate mining region. 
  • Lung cancer in North Carolina. 
  • Lung cancer management in 2010. 
  • Lung cancer staging and management: comparison of contrast-enhanced and nonenhanced helical CT of the thorax. 
  • MEN1 gene mutation analysis of high-grade neuroendocrine lung carcinoma. 
  • Maintenance daily oral etoposide versus no further therapy following induction chemotherapy with etoposide plus ifosfamide plus cisplatin in extensive small-cell lung cancer: a Hoosier Oncology Group randomized study. 
  • Methodology for lung cancer evidence review and guideline development: ACCP evidence-based clinical practice guidelines (2nd Edition). 
  • Mitomycin C and menadione for the treatment of lung cancer: a phase II trial. 
  • Modeling killing and repopulation kinetics of subclinical cancer: direct calculations from clinical data. 
  • Molecular characterization of the human delta opioid receptor in lung cancer. 
  • Molecular classification and molecular genetics of human lung cancers. 
  • Neuroendocrine carcinoma of the oral cavity. 
  • Neuroendocrine cells of prostate cancer: biologic functions and molecular mechanisms. 
  • Neuroendocrine small cell carcinoma of the uterine cervix: what disease? What treatment? Report of ten cases and a review of the literature. 
  • Neuropsychological effects of cranial radiation: current knowledge and future directions. 
  • Notch-1 regulates pulmonary neuroendocrine cell differentiation in cell lines and in transgenic mice. 
  • Overview of genetic and molecular events in the pathogenesis of lung cancer. 
  • PC3 is a cell line characteristic of prostatic small cell carcinoma. 
  • Paclitaxel by 96-hour continuous infusion in combination with cisplatin: a phase I trial in patients with advanced lung cancer. 
  • Pan-cancer Convergence to a Small-Cell Neuroendocrine Phenotype that Shares Susceptibilities with Hematological Malignancies. 
  • Pathogenesis of prostatic small cell carcinoma involves the inactivation of the P53 pathway. 
  • Performance characteristics of different modalities for diagnosis of suspected lung cancer: summary of published evidence. 
  • Phase I study to determine the maximum-tolerated dose of radiation in standard daily and hyperfractionated-accelerated twice-daily radiation schedules with concurrent chemotherapy for limited-stage small-cell lung cancer. 
  • Phase I trial of etoposide, carboplatin, and GM-CSF in extensive small-cell lung cancer: a Cancer and Leukemia Group B study (CALGB 8832). 
  • Phase II evaluation of aclarubicin in lung cancer: a Southeastern Cancer Study Group Trial. 
  • Phase II study of carboplatin, irinotecan, and thalidomide combination in patients with extensive stage small-cell lung cancer. 
  • Phase II trial of irinotecan/gemcitabine as second-line therapy for relapsed and refractory small-cell lung cancer: Cancer and Leukemia Group B Study 39902. 
  • Phase II trial of paclitaxel-topotecan-etoposide followed by consolidation chemoradiotherapy for limited-stage small cell lung cancer: CALGB 30002. 
  • Phase II trial of vinorelbine plus doxorubicin in relapsed small-cell lung cancer: CALGB 9332. 
  • Phase II trial of weekly dose-dense paclitaxel in extensive-stage small cell lung cancer: cancer and leukemia group B study 39901. 
  • Phase III Randomized, Placebo-Controlled, Double-Blind Trial of Celecoxib in Addition to Standard Chemotherapy for Advanced Non-Small-Cell Lung Cancer With Cyclooxygenase-2 Overexpression: CALGB 30801 (Alliance). 
  • Polymorphisms in excision repair cross-complementing group 4 (ERCC4) and susceptibility to primary lung cancer in a Chinese Han population. 
  • Polymorphisms in the two helicases ERCC2/XPD and ERCC3/XPB of the transcription factor IIH complex and risk of lung cancer: a case-control analysis in a Chinese population. 
  • Potentially functional polymorphisms of EXO1 and risk of lung cancer in a Chinese population: A case-control analysis. 
  • Prognostic indicators for survival in stage I carcinoma of the lung: a histologic study of 47 surgically resected cases. 
  • Protein expression and functional analysis of the FHIT gene in human tumor cells. 
  • Protocol for the examination of specimens from patients with primary non-small cell carcinoma, small cell carcinoma, or carcinoid tumor of the lung. 
  • Psychologic and neuropsychologic functioning of patients with limited small-cell lung cancer treated with chemotherapy and radiation therapy with or without warfarin: a study by the Cancer and Leukemia Group B. 
  • Radiotherapy and Small Cell Carcinoma With Paraneoplastic Polyneuropathy: A Case Report. 
  • Randomized double-blind placebo-controlled trial of cisplatin and etoposide plus megestrol acetate/placebo in extensive-stage small-cell lung cancer: a North Central Cancer Treatment Group study. 
  • Randomized phase II Study of carboplatin and etoposide with or without the bcl-2 antisense oligonucleotide oblimersen for extensive-stage small-cell lung cancer: CALGB 30103. 
  • Randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage small-cell lung cancer: Cancer and Leukemia Group B Trial 9732. 
  • Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group. 
  • Randomized trial of chemotherapy and radiation therapy with or without warfarin for limited-stage small-cell lung cancer: a Cancer and Leukemia Group B study. 
  • Randomized trial of combined modality therapy with and without thymosin fraction V in the treatment of small cell lung cancer. 
  • Randomized trial of radiotherapy to the thorax in limited small-cell carcinoma of the lung treated with multiagent chemotherapy and elective brain irradiation: a preliminary report. 
  • Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. 
  • Reduction of oral mucositis by filgrastim (r-metHuG-CSF) in patients receiving chemotherapy. 
  • Response of the secretory immune system to bronchogenic carcinoma of the lung. 
  • Retreatment of patients surviving cancer-free 2 or more years after initial treatment of small cell lung cancer. 
  • Role of Adjuvant Therapy in a Population-Based Cohort of Patients With Early-Stage Small-Cell Lung Cancer. 
  • Role of computerized cranial tomography in the staging of small cell carcinoma of the lung. 
  • Routine use of approximately 60 Gy once-daily thoracic irradiation for patients with limited-stage small-cell lung cancer. 
  • Safety of topotecan in the treatment of recurrent small-cell lung cancer and ovarian cancer. 
  • Schedule dependency of 21-day oral versus 3-day intravenous etoposide in combination with intravenous cisplatin in extensive-stage small-cell lung cancer: a randomized phase III study of the Cancer and Leukemia Group B. 
  • Similar outcomes between African American and non-African American patients with extensive-stage small-cell lung carcinoma: report from the Cancer and Leukemia Group B. 
  • Small cell and large cell neuroendocrine carcinomas of the pancreas are genetically similar and distinct from well-differentiated pancreatic neuroendocrine tumors. 
  • Small cell bladder cancer: should we consider prophylactic cranial irradiation? 
  • Small cell carcinoma of the lung. Results of combination chemotherapy and radiation therapy. 
  • Small cell carcinoma of the prostate: an immunohistochemical study. 
  • Small cell lung cancer clinical practice guidelines in oncology. 
  • Small cell lung cancer presenting as a paraneoplastic syndrome characterized by recurrent episodic hypotension and bradycardia: case report. 
  • Small cell lung cancer. 
  • Small cell lung carcinoma cell lines express mRNA for calcitonin and alpha- and beta-calcitonin gene related peptides. 
  • Small-cell lung cancer: a review of clinical trials. 
  • Stage 1 small cell cancer of the vagina. 
  • Stage I small cell carcinoma of the vulva treated with vulvectomy, lymphadenectomy, and adjuvant chemotherapy. 
  • Staging non-small cell lung cancer with whole-body PET. 
  • Subcutaneous interleukin-2 as initial therapy for patients with extensive small cell lung cancer: a phase II trial of Cancer and Leukemia Group B. 
  • Successful clinical response to irinotecan in desmoplastic round blue cell tumor. 
  • Sudden death in cancer patients receiving lithium. 
  • Syndrome of inappropriate antidiuretic hormone secretion. 
  • TaqMan junction probes and the reverse transcriptase polymerase chain reaction: detection of alveolar rhabdomyosarcoma, synovial sarcoma, and desmoplastic small round cell tumor. 
  • Targeted cytotoxic analogue of bombesin/gastrin-releasing peptide inhibits the growth of H-69 human small-cell lung carcinoma in nude mice. 
  • The Role of CD44 in Glucose Metabolism in Prostatic Small Cell Neuroendocrine Carcinoma. 
  • The health-related quality of life and survival of small-cell lung cancer patients: results of a companion study to CALGB 9033. 
  • The hereditary nature of small cell carcinoma of the ovary, hypercalcemic type: two new familial cases. 
  • The impact of Filgrastim schedule variation on hematopoietic recovery post-chemotherapy. 
  • The impact of pre-radiotherapy surgery on radiation-induced lung injury. 
  • The impact of therapy with filgrastim (recombinant granulocyte colony-stimulating factor) on the health care costs associated with cancer chemotherapy. 
  • The importance of chemotherapy dose intensity in lung cancer. 
  • The influence of clinical and genetic factors on patient outcome in small cell carcinoma of the ovary, hypercalcemic type. 
  • The radiographic diagnosis and treatment of paraneoplastic central nervous system disease. 
  • The synthetic phosphagen cyclocreatine phosphate inhibits the growth of a broad spectrum of solid tumors. 
  • The use of a panel of monoclonal antibodies in ultrastructurally characterized small cell carcinomas of the lung. 
  • The use of lithium carbonate to reduce infection and leukopenia during systemic chemotherapy. 
  • Thoracic radiation therapy added to chemotherapy for small-cell lung cancer: an update of Cancer and Leukemia Group B Study 8083. 
  • Tirapazamine: a hypoxia-activated topoisomerase II poison. 
  • Tobacco components stimulate Akt-dependent proliferation and NFkappaB-dependent survival in lung cancer cells. 
  • Topotecan in the treatment of elderly patients with relapsed small-cell lung cancer. 
  • Tumor necrosis factor induces neuroendocrine differentiation in small cell lung cancer cell lines. 
  • Virtual bronchoscopy for directing transbronchial needle aspiration of hilar and mediastinal lymph nodes: a pilot study. 
  • [Neuroendocrine differentiation in prostate cancer]. 
  • p53 Mutation Directs AURKA Overexpression via miR-25 and FBXW7 in Prostatic Small Cell Neuroendocrine Carcinoma. 
• 

  Keywords of People

  • Berchuck, Andrew, James M. Ingram Distinguished Professor of Gynecologic Oncology, Obstetrics and Gynecology, Gynecologic Oncology
  • Patz Jr., Edward F., James and Alice Chen Distinguished Professor of Radiology, Pathology
  • Sunday, Mary Elizabeth Anne, Professor of Pathology, Cell Biology